Could Moderna be the next big opportunity in biotech? Join our experts as they dissect the company's strengths and weaknesses, revealing insights that could shape your investment strategy.
Looking back on therapeutics stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers. Over the ...
The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting $62.97 per share. This was partly th...
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Natera (NASDAQ:NTRA) and its ...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 2.6% in the afternoon session after the European Commission signed a contract to ...
MarketBeat's weekly roundup covers a weaker June jobs report, tech sector rotation, and top analyst picks including TSLA, AVGO, PLTR, MRNA, and NEE heading into Q2 earnings season.
